
Global Valsartan Market Outlook and Growth Opportunities 2025
Description
Summary
According to APO Research, the global Valsartan market is projected to grow from US$ million in 2025 to US$ million by 2031, at a compound annual growth rate (CAGR) of % during the forecast period.
The North American market for Valsartan is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The Asia-Pacific market for Valsartan is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
In China, the Valsartan market is expected to rise from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The Europe market for Valsartan is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Major global companies in the Valsartan market include Alembic Pharmaceuticals, Amneal Pharmaceuticals, Aurobindo Pharma, HETERO, Huaren Pharmaceutical, Jubilant Pharma, LG Life Sciences, Lupin and Macleods Pharmaceuticals, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.
This report presents an overview of global market for Valsartan, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2020 - 2024, estimates for 2025, and projections of CAGR through 2031.
This report researches the key producers of Valsartan, also provides the sales of main regions and countries. Of the upcoming market potential for Valsartan, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Valsartan sales, revenue, market share and industry ranking of main manufacturers, data from 2020 to 2025. Identification of the major stakeholders in the global Valsartan market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2020 to 2031. Evaluation and forecast the market size for Valsartan sales, projected growth trends, production technology, application and end-user industry.
Valsartan Segment by Company
Alembic Pharmaceuticals
Amneal Pharmaceuticals
Aurobindo Pharma
HETERO
Huaren Pharmaceutical
Jubilant Pharma
LG Life Sciences
Lupin
Macleods Pharmaceuticals
Square Pharmaceuticals
Torrent Pharmaceuticals
Unichem Laboratories
Mylan
Novartis
Sun Pharmaceutical
Teva
Zhejiang Huahai Pharmaceutical
Valsartan Segment by Type
80 mg Tablets
40 mg Tablets
320 mg Tablets
160 mg Tablets
Valsartan Segment by Application
Heart Failure
Heart Attack
Hypertension
Valsartan Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Study Objectives
1. To analyze and research the global Valsartan status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions Valsartan market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify Valsartan significant trends, drivers, influence factors in global and regions.
6. To analyze Valsartan competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Valsartan market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Valsartan and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Valsartan.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Provides an overview of the Valsartan market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2020-2031).
Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Valsartan industry.
Chapter 3: Detailed analysis of Valsartan manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales and value of Valsartan in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 7: Sales and value of Valsartan in country level. It provides sigmate data by type, and by application for each country/region.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights.
According to APO Research, the global Valsartan market is projected to grow from US$ million in 2025 to US$ million by 2031, at a compound annual growth rate (CAGR) of % during the forecast period.
The North American market for Valsartan is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The Asia-Pacific market for Valsartan is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
In China, the Valsartan market is expected to rise from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The Europe market for Valsartan is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Major global companies in the Valsartan market include Alembic Pharmaceuticals, Amneal Pharmaceuticals, Aurobindo Pharma, HETERO, Huaren Pharmaceutical, Jubilant Pharma, LG Life Sciences, Lupin and Macleods Pharmaceuticals, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.
This report presents an overview of global market for Valsartan, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2020 - 2024, estimates for 2025, and projections of CAGR through 2031.
This report researches the key producers of Valsartan, also provides the sales of main regions and countries. Of the upcoming market potential for Valsartan, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Valsartan sales, revenue, market share and industry ranking of main manufacturers, data from 2020 to 2025. Identification of the major stakeholders in the global Valsartan market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2020 to 2031. Evaluation and forecast the market size for Valsartan sales, projected growth trends, production technology, application and end-user industry.
Valsartan Segment by Company
Alembic Pharmaceuticals
Amneal Pharmaceuticals
Aurobindo Pharma
HETERO
Huaren Pharmaceutical
Jubilant Pharma
LG Life Sciences
Lupin
Macleods Pharmaceuticals
Square Pharmaceuticals
Torrent Pharmaceuticals
Unichem Laboratories
Mylan
Novartis
Sun Pharmaceutical
Teva
Zhejiang Huahai Pharmaceutical
Valsartan Segment by Type
80 mg Tablets
40 mg Tablets
320 mg Tablets
160 mg Tablets
Valsartan Segment by Application
Heart Failure
Heart Attack
Hypertension
Valsartan Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Study Objectives
1. To analyze and research the global Valsartan status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions Valsartan market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify Valsartan significant trends, drivers, influence factors in global and regions.
6. To analyze Valsartan competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Valsartan market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Valsartan and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Valsartan.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Provides an overview of the Valsartan market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2020-2031).
Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Valsartan industry.
Chapter 3: Detailed analysis of Valsartan manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales and value of Valsartan in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 7: Sales and value of Valsartan in country level. It provides sigmate data by type, and by application for each country/region.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights.
Table of Contents
202 Pages
- 1 Market Overview
- 1.1 Product Definition
- 1.2 Global Market Growth Prospects
- 1.2.1 Global Valsartan Sales Value (2020-2031)
- 1.2.2 Global Valsartan Sales Volume (2020-2031)
- 1.2.3 Global Valsartan Sales Average Price (2020-2031)
- 1.3 Assumptions and Limitations
- 1.4 Study Goals and Objectives
- 2 Valsartan Market Dynamics
- 2.1 Valsartan Industry Trends
- 2.2 Valsartan Industry Drivers
- 2.3 Valsartan Industry Opportunities and Challenges
- 2.4 Valsartan Industry Restraints
- 3 Valsartan Market by Company
- 3.1 Global Valsartan Company Revenue Ranking in 2024
- 3.2 Global Valsartan Revenue by Company (2020-2025)
- 3.3 Global Valsartan Sales Volume by Company (2020-2025)
- 3.4 Global Valsartan Average Price by Company (2020-2025)
- 3.5 Global Valsartan Company Ranking (2023-2025)
- 3.6 Global Valsartan Company Manufacturing Base and Headquarters
- 3.7 Global Valsartan Company Product Type and Application
- 3.8 Global Valsartan Company Establishment Date
- 3.9 Market Competitive Analysis
- 3.9.1 Global Valsartan Market Concentration Ratio (CR5 and HHI)
- 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2024
- 3.9.3 2024 Valsartan Tier 1, Tier 2, and Tier 3 Companies
- 3.10 Mergers and Acquisitions Expansion
- 4 Valsartan Market by Type
- 4.1 Valsartan Type Introduction
- 4.1.1 80 mg Tablets
- 4.1.2 40 mg Tablets
- 4.1.3 320 mg Tablets
- 4.1.4 160 mg Tablets
- 4.2 Global Valsartan Sales Volume by Type
- 4.2.1 Global Valsartan Sales Volume by Type (2020 VS 2024 VS 2031)
- 4.2.2 Global Valsartan Sales Volume by Type (2020-2031)
- 4.2.3 Global Valsartan Sales Volume Share by Type (2020-2031)
- 4.3 Global Valsartan Sales Value by Type
- 4.3.1 Global Valsartan Sales Value by Type (2020 VS 2024 VS 2031)
- 4.3.2 Global Valsartan Sales Value by Type (2020-2031)
- 4.3.3 Global Valsartan Sales Value Share by Type (2020-2031)
- 5 Valsartan Market by Application
- 5.1 Valsartan Application Introduction
- 5.1.1 Heart Failure
- 5.1.2 Heart Attack
- 5.1.3 Hypertension
- 5.2 Global Valsartan Sales Volume by Application
- 5.2.1 Global Valsartan Sales Volume by Application (2020 VS 2024 VS 2031)
- 5.2.2 Global Valsartan Sales Volume by Application (2020-2031)
- 5.2.3 Global Valsartan Sales Volume Share by Application (2020-2031)
- 5.3 Global Valsartan Sales Value by Application
- 5.3.1 Global Valsartan Sales Value by Application (2020 VS 2024 VS 2031)
- 5.3.2 Global Valsartan Sales Value by Application (2020-2031)
- 5.3.3 Global Valsartan Sales Value Share by Application (2020-2031)
- 6 Valsartan Regional Sales and Value Analysis
- 6.1 Global Valsartan Sales by Region: 2020 VS 2024 VS 2031
- 6.2 Global Valsartan Sales by Region (2020-2031)
- 6.2.1 Global Valsartan Sales by Region: 2020-2025
- 6.2.2 Global Valsartan Sales by Region (2026-2031)
- 6.3 Global Valsartan Sales Value by Region: 2020 VS 2024 VS 2031
- 6.4 Global Valsartan Sales Value by Region (2020-2031)
- 6.4.1 Global Valsartan Sales Value by Region: 2020-2025
- 6.4.2 Global Valsartan Sales Value by Region (2026-2031)
- 6.5 Global Valsartan Market Price Analysis by Region (2020-2025)
- 6.6 North America
- 6.6.1 North America Valsartan Sales Value (2020-2031)
- 6.6.2 North America Valsartan Sales Value Share by Country, 2024 VS 2031
- 6.7 Europe
- 6.7.1 Europe Valsartan Sales Value (2020-2031)
- 6.7.2 Europe Valsartan Sales Value Share by Country, 2024 VS 2031
- 6.8 Asia-Pacific
- 6.8.1 Asia-Pacific Valsartan Sales Value (2020-2031)
- 6.8.2 Asia-Pacific Valsartan Sales Value Share by Country, 2024 VS 2031
- 6.9 South America
- 6.9.1 South America Valsartan Sales Value (2020-2031)
- 6.9.2 South America Valsartan Sales Value Share by Country, 2024 VS 2031
- 6.10 Middle East & Africa
- 6.10.1 Middle East & Africa Valsartan Sales Value (2020-2031)
- 6.10.2 Middle East & Africa Valsartan Sales Value Share by Country, 2024 VS 2031
- 7 Valsartan Country-level Sales and Value Analysis
- 7.1 Global Valsartan Sales by Country: 2020 VS 2024 VS 2031
- 7.2 Global Valsartan Sales Value by Country: 2020 VS 2024 VS 2031
- 7.3 Global Valsartan Sales by Country (2020-2031)
- 7.3.1 Global Valsartan Sales by Country (2020-2025)
- 7.3.2 Global Valsartan Sales by Country (2026-2031)
- 7.4 Global Valsartan Sales Value by Country (2020-2031)
- 7.4.1 Global Valsartan Sales Value by Country (2020-2025)
- 7.4.2 Global Valsartan Sales Value by Country (2026-2031)
- 7.5 USA
- 7.5.1 USA Valsartan Sales Value Growth Rate (2020-2031)
- 7.5.2 USA Valsartan Sales Value Share by Type, 2024 VS 2031
- 7.5.3 USA Valsartan Sales Value Share by Application, 2024 VS 2031
- 7.6 Canada
- 7.6.1 Canada Valsartan Sales Value Growth Rate (2020-2031)
- 7.6.2 Canada Valsartan Sales Value Share by Type, 2024 VS 2031
- 7.6.3 Canada Valsartan Sales Value Share by Application, 2024 VS 2031
- 7.7 Mexico
- 7.6.1 Mexico Valsartan Sales Value Growth Rate (2020-2031)
- 7.6.2 Mexico Valsartan Sales Value Share by Type, 2024 VS 2031
- 7.6.3 Mexico Valsartan Sales Value Share by Application, 2024 VS 2031
- 7.8 Germany
- 7.8.1 Germany Valsartan Sales Value Growth Rate (2020-2031)
- 7.8.2 Germany Valsartan Sales Value Share by Type, 2024 VS 2031
- 7.8.3 Germany Valsartan Sales Value Share by Application, 2024 VS 2031
- 7.9 France
- 7.9.1 France Valsartan Sales Value Growth Rate (2020-2031)
- 7.9.2 France Valsartan Sales Value Share by Type, 2024 VS 2031
- 7.9.3 France Valsartan Sales Value Share by Application, 2024 VS 2031
- 7.10 U.K.
- 7.10.1 U.K. Valsartan Sales Value Growth Rate (2020-2031)
- 7.10.2 U.K. Valsartan Sales Value Share by Type, 2024 VS 2031
- 7.10.3 U.K. Valsartan Sales Value Share by Application, 2024 VS 2031
- 7.11 Italy
- 7.11.1 Italy Valsartan Sales Value Growth Rate (2020-2031)
- 7.11.2 Italy Valsartan Sales Value Share by Type, 2024 VS 2031
- 7.11.3 Italy Valsartan Sales Value Share by Application, 2024 VS 2031
- 7.12 Spain
- 7.12.1 Spain Valsartan Sales Value Growth Rate (2020-2031)
- 7.12.2 Spain Valsartan Sales Value Share by Type, 2024 VS 2031
- 7.12.3 Spain Valsartan Sales Value Share by Application, 2024 VS 2031
- 7.13 Russia
- 7.13.1 Russia Valsartan Sales Value Growth Rate (2020-2031)
- 7.13.2 Russia Valsartan Sales Value Share by Type, 2024 VS 2031
- 7.13.3 Russia Valsartan Sales Value Share by Application, 2024 VS 2031
- 7.14 Netherlands
- 7.14.1 Netherlands Valsartan Sales Value Growth Rate (2020-2031)
- 7.14.2 Netherlands Valsartan Sales Value Share by Type, 2024 VS 2031
- 7.14.3 Netherlands Valsartan Sales Value Share by Application, 2024 VS 2031
- 7.15 Nordic Countries
- 7.15.1 Nordic Countries Valsartan Sales Value Growth Rate (2020-2031)
- 7.15.2 Nordic Countries Valsartan Sales Value Share by Type, 2024 VS 2031
- 7.15.3 Nordic Countries Valsartan Sales Value Share by Application, 2024 VS 2031
- 7.16 China
- 7.16.1 China Valsartan Sales Value Growth Rate (2020-2031)
- 7.16.2 China Valsartan Sales Value Share by Type, 2024 VS 2031
- 7.16.3 China Valsartan Sales Value Share by Application, 2024 VS 2031
- 7.17 Japan
- 7.17.1 Japan Valsartan Sales Value Growth Rate (2020-2031)
- 7.17.2 Japan Valsartan Sales Value Share by Type, 2024 VS 2031
- 7.17.3 Japan Valsartan Sales Value Share by Application, 2024 VS 2031
- 7.18 South Korea
- 7.18.1 South Korea Valsartan Sales Value Growth Rate (2020-2031)
- 7.18.2 South Korea Valsartan Sales Value Share by Type, 2024 VS 2031
- 7.18.3 South Korea Valsartan Sales Value Share by Application, 2024 VS 2031
- 7.19 India
- 7.19.1 India Valsartan Sales Value Growth Rate (2020-2031)
- 7.19.2 India Valsartan Sales Value Share by Type, 2024 VS 2031
- 7.19.3 India Valsartan Sales Value Share by Application, 2024 VS 2031
- 7.20 Australia
- 7.20.1 Australia Valsartan Sales Value Growth Rate (2020-2031)
- 7.20.2 Australia Valsartan Sales Value Share by Type, 2024 VS 2031
- 7.20.3 Australia Valsartan Sales Value Share by Application, 2024 VS 2031
- 7.21 Southeast Asia
- 7.21.1 Southeast Asia Valsartan Sales Value Growth Rate (2020-2031)
- 7.21.2 Southeast Asia Valsartan Sales Value Share by Type, 2024 VS 2031
- 7.21.3 Southeast Asia Valsartan Sales Value Share by Application, 2024 VS 2031
- 7.22 Brazil
- 7.22.1 Brazil Valsartan Sales Value Growth Rate (2020-2031)
- 7.22.2 Brazil Valsartan Sales Value Share by Type, 2024 VS 2031
- 7.22.3 Brazil Valsartan Sales Value Share by Application, 2024 VS 2031
- 7.23 Argentina
- 7.23.1 Argentina Valsartan Sales Value Growth Rate (2020-2031)
- 7.23.2 Argentina Valsartan Sales Value Share by Type, 2024 VS 2031
- 7.23.3 Argentina Valsartan Sales Value Share by Application, 2024 VS 2031
- 7.24 Chile
- 7.24.1 Chile Valsartan Sales Value Growth Rate (2020-2031)
- 7.24.2 Chile Valsartan Sales Value Share by Type, 2024 VS 2031
- 7.24.3 Chile Valsartan Sales Value Share by Application, 2024 VS 2031
- 7.25 Colombia
- 7.25.1 Colombia Valsartan Sales Value Growth Rate (2020-2031)
- 7.25.2 Colombia Valsartan Sales Value Share by Type, 2024 VS 2031
- 7.25.3 Colombia Valsartan Sales Value Share by Application, 2024 VS 2031
- 7.26 Peru
- 7.26.1 Peru Valsartan Sales Value Growth Rate (2020-2031)
- 7.26.2 Peru Valsartan Sales Value Share by Type, 2024 VS 2031
- 7.26.3 Peru Valsartan Sales Value Share by Application, 2024 VS 2031
- 7.27 Saudi Arabia
- 7.27.1 Saudi Arabia Valsartan Sales Value Growth Rate (2020-2031)
- 7.27.2 Saudi Arabia Valsartan Sales Value Share by Type, 2024 VS 2031
- 7.27.3 Saudi Arabia Valsartan Sales Value Share by Application, 2024 VS 2031
- 7.28 Israel
- 7.28.1 Israel Valsartan Sales Value Growth Rate (2020-2031)
- 7.28.2 Israel Valsartan Sales Value Share by Type, 2024 VS 2031
- 7.28.3 Israel Valsartan Sales Value Share by Application, 2024 VS 2031
- 7.29 UAE
- 7.29.1 UAE Valsartan Sales Value Growth Rate (2020-2031)
- 7.29.2 UAE Valsartan Sales Value Share by Type, 2024 VS 2031
- 7.29.3 UAE Valsartan Sales Value Share by Application, 2024 VS 2031
- 7.30 Turkey
- 7.30.1 Turkey Valsartan Sales Value Growth Rate (2020-2031)
- 7.30.2 Turkey Valsartan Sales Value Share by Type, 2024 VS 2031
- 7.30.3 Turkey Valsartan Sales Value Share by Application, 2024 VS 2031
- 7.31 Iran
- 7.31.1 Iran Valsartan Sales Value Growth Rate (2020-2031)
- 7.31.2 Iran Valsartan Sales Value Share by Type, 2024 VS 2031
- 7.31.3 Iran Valsartan Sales Value Share by Application, 2024 VS 2031
- 7.32 Egypt
- 7.32.1 Egypt Valsartan Sales Value Growth Rate (2020-2031)
- 7.32.2 Egypt Valsartan Sales Value Share by Type, 2024 VS 2031
- 7.32.3 Egypt Valsartan Sales Value Share by Application, 2024 VS 2031
- 8 Company Profiles
- 8.1 Alembic Pharmaceuticals
- 8.1.1 Alembic Pharmaceuticals Comapny Information
- 8.1.2 Alembic Pharmaceuticals Business Overview
- 8.1.3 Alembic Pharmaceuticals Valsartan Sales, Value and Gross Margin (2020-2025)
- 8.1.4 Alembic Pharmaceuticals Valsartan Product Portfolio
- 8.1.5 Alembic Pharmaceuticals Recent Developments
- 8.2 Amneal Pharmaceuticals
- 8.2.1 Amneal Pharmaceuticals Comapny Information
- 8.2.2 Amneal Pharmaceuticals Business Overview
- 8.2.3 Amneal Pharmaceuticals Valsartan Sales, Value and Gross Margin (2020-2025)
- 8.2.4 Amneal Pharmaceuticals Valsartan Product Portfolio
- 8.2.5 Amneal Pharmaceuticals Recent Developments
- 8.3 Aurobindo Pharma
- 8.3.1 Aurobindo Pharma Comapny Information
- 8.3.2 Aurobindo Pharma Business Overview
- 8.3.3 Aurobindo Pharma Valsartan Sales, Value and Gross Margin (2020-2025)
- 8.3.4 Aurobindo Pharma Valsartan Product Portfolio
- 8.3.5 Aurobindo Pharma Recent Developments
- 8.4 HETERO
- 8.4.1 HETERO Comapny Information
- 8.4.2 HETERO Business Overview
- 8.4.3 HETERO Valsartan Sales, Value and Gross Margin (2020-2025)
- 8.4.4 HETERO Valsartan Product Portfolio
- 8.4.5 HETERO Recent Developments
- 8.5 Huaren Pharmaceutical
- 8.5.1 Huaren Pharmaceutical Comapny Information
- 8.5.2 Huaren Pharmaceutical Business Overview
- 8.5.3 Huaren Pharmaceutical Valsartan Sales, Value and Gross Margin (2020-2025)
- 8.5.4 Huaren Pharmaceutical Valsartan Product Portfolio
- 8.5.5 Huaren Pharmaceutical Recent Developments
- 8.6 Jubilant Pharma
- 8.6.1 Jubilant Pharma Comapny Information
- 8.6.2 Jubilant Pharma Business Overview
- 8.6.3 Jubilant Pharma Valsartan Sales, Value and Gross Margin (2020-2025)
- 8.6.4 Jubilant Pharma Valsartan Product Portfolio
- 8.6.5 Jubilant Pharma Recent Developments
- 8.7 LG Life Sciences
- 8.7.1 LG Life Sciences Comapny Information
- 8.7.2 LG Life Sciences Business Overview
- 8.7.3 LG Life Sciences Valsartan Sales, Value and Gross Margin (2020-2025)
- 8.7.4 LG Life Sciences Valsartan Product Portfolio
- 8.7.5 LG Life Sciences Recent Developments
- 8.8 Lupin
- 8.8.1 Lupin Comapny Information
- 8.8.2 Lupin Business Overview
- 8.8.3 Lupin Valsartan Sales, Value and Gross Margin (2020-2025)
- 8.8.4 Lupin Valsartan Product Portfolio
- 8.8.5 Lupin Recent Developments
- 8.9 Macleods Pharmaceuticals
- 8.9.1 Macleods Pharmaceuticals Comapny Information
- 8.9.2 Macleods Pharmaceuticals Business Overview
- 8.9.3 Macleods Pharmaceuticals Valsartan Sales, Value and Gross Margin (2020-2025)
- 8.9.4 Macleods Pharmaceuticals Valsartan Product Portfolio
- 8.9.5 Macleods Pharmaceuticals Recent Developments
- 8.10 Square Pharmaceuticals
- 8.10.1 Square Pharmaceuticals Comapny Information
- 8.10.2 Square Pharmaceuticals Business Overview
- 8.10.3 Square Pharmaceuticals Valsartan Sales, Value and Gross Margin (2020-2025)
- 8.10.4 Square Pharmaceuticals Valsartan Product Portfolio
- 8.10.5 Square Pharmaceuticals Recent Developments
- 8.11 Torrent Pharmaceuticals
- 8.11.1 Torrent Pharmaceuticals Comapny Information
- 8.11.2 Torrent Pharmaceuticals Business Overview
- 8.11.3 Torrent Pharmaceuticals Valsartan Sales, Value and Gross Margin (2020-2025)
- 8.11.4 Torrent Pharmaceuticals Valsartan Product Portfolio
- 8.11.5 Torrent Pharmaceuticals Recent Developments
- 8.12 Unichem Laboratories
- 8.12.1 Unichem Laboratories Comapny Information
- 8.12.2 Unichem Laboratories Business Overview
- 8.12.3 Unichem Laboratories Valsartan Sales, Value and Gross Margin (2020-2025)
- 8.12.4 Unichem Laboratories Valsartan Product Portfolio
- 8.12.5 Unichem Laboratories Recent Developments
- 8.13 Mylan
- 8.13.1 Mylan Comapny Information
- 8.13.2 Mylan Business Overview
- 8.13.3 Mylan Valsartan Sales, Value and Gross Margin (2020-2025)
- 8.13.4 Mylan Valsartan Product Portfolio
- 8.13.5 Mylan Recent Developments
- 8.14 Novartis
- 8.14.1 Novartis Comapny Information
- 8.14.2 Novartis Business Overview
- 8.14.3 Novartis Valsartan Sales, Value and Gross Margin (2020-2025)
- 8.14.4 Novartis Valsartan Product Portfolio
- 8.14.5 Novartis Recent Developments
- 8.15 Sun Pharmaceutical
- 8.15.1 Sun Pharmaceutical Comapny Information
- 8.15.2 Sun Pharmaceutical Business Overview
- 8.15.3 Sun Pharmaceutical Valsartan Sales, Value and Gross Margin (2020-2025)
- 8.15.4 Sun Pharmaceutical Valsartan Product Portfolio
- 8.15.5 Sun Pharmaceutical Recent Developments
- 8.16 Teva
- 8.16.1 Teva Comapny Information
- 8.16.2 Teva Business Overview
- 8.16.3 Teva Valsartan Sales, Value and Gross Margin (2020-2025)
- 8.16.4 Teva Valsartan Product Portfolio
- 8.16.5 Teva Recent Developments
- 8.17 Zhejiang Huahai Pharmaceutical
- 8.17.1 Zhejiang Huahai Pharmaceutical Comapny Information
- 8.17.2 Zhejiang Huahai Pharmaceutical Business Overview
- 8.17.3 Zhejiang Huahai Pharmaceutical Valsartan Sales, Value and Gross Margin (2020-2025)
- 8.17.4 Zhejiang Huahai Pharmaceutical Valsartan Product Portfolio
- 8.17.5 Zhejiang Huahai Pharmaceutical Recent Developments
- 9 Value Chain and Sales Channels Analysis
- 9.1 Valsartan Value Chain Analysis
- 9.1.1 Valsartan Key Raw Materials
- 9.1.2 Raw Materials Key Suppliers
- 9.1.3 Manufacturing Cost Structure
- 9.1.4 Valsartan Sales Mode & Process
- 9.2 Valsartan Sales Channels Analysis
- 9.2.1 Direct Comparison with Distribution Share
- 9.2.2 Valsartan Distributors
- 9.2.3 Valsartan Customers
- 10 Concluding Insights
- 11 Appendix
- 11.1 Reasons for Doing This Study
- 11.2 Research Methodology
- 11.3 Research Process
- 11.4 Authors List of This Report
- 11.5 Data Source
- 11.5.1 Secondary Sources
- 11.5.2 Primary Sources
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.